nodes	percent_of_prediction	percent_of_DWPC	metapath
Reboxetine—ABCB1—Mitomycin—urinary bladder cancer	0.203	0.361	CbGbCtD
Reboxetine—CYP3A4—Thiotepa—urinary bladder cancer	0.0921	0.164	CbGbCtD
Reboxetine—ABCB1—Gemcitabine—urinary bladder cancer	0.0584	0.104	CbGbCtD
Reboxetine—ABCB1—Cisplatin—urinary bladder cancer	0.0424	0.0754	CbGbCtD
Reboxetine—ABCB1—Etoposide—urinary bladder cancer	0.0417	0.0741	CbGbCtD
Reboxetine—ABCB1—Doxorubicin—urinary bladder cancer	0.0284	0.0506	CbGbCtD
Reboxetine—ABCB1—Methotrexate—urinary bladder cancer	0.0275	0.049	CbGbCtD
Reboxetine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0268	0.0476	CbGbCtD
Reboxetine—CYP3A4—Etoposide—urinary bladder cancer	0.025	0.0444	CbGbCtD
Reboxetine—CYP3A4—Doxorubicin—urinary bladder cancer	0.017	0.0303	CbGbCtD
Reboxetine—ABCB1—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00257	0.0697	CbGpPWpGaD
Reboxetine—CYP2D6—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00242	0.0657	CbGpPWpGaD
Reboxetine—SLC6A2—Amine compound SLC transporters—SLC14A2—urinary bladder cancer	0.00222	0.0601	CbGpPWpGaD
Reboxetine—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00158	0.043	CbGpPWpGaD
Reboxetine—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.00158	0.0428	CbGpPWpGaD
Reboxetine—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.00132	0.0358	CbGpPWpGaD
Reboxetine—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00112	0.0304	CbGpPWpGaD
Reboxetine—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000908	0.0246	CbGpPWpGaD
Reboxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.000867	0.0235	CbGpPWpGaD
Reboxetine—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.000828	0.0225	CbGpPWpGaD
Reboxetine—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.000732	0.0199	CbGpPWpGaD
Reboxetine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000727	0.0197	CbGpPWpGaD
Reboxetine—SLC6A4—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000665	0.018	CbGpPWpGaD
Reboxetine—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000594	0.0161	CbGpPWpGaD
Reboxetine—SLC6A2—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000572	0.0155	CbGpPWpGaD
Reboxetine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000521	0.0141	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.000479	0.013	CbGpPWpGaD
Reboxetine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000448	0.0122	CbGpPWpGaD
Reboxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000435	0.0118	CbGpPWpGaD
Reboxetine—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000429	0.0116	CbGpPWpGaD
Reboxetine—SLC6A2—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000394	0.0107	CbGpPWpGaD
Reboxetine—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000373	0.0101	CbGpPWpGaD
Reboxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000353	0.00957	CbGpPWpGaD
Reboxetine—Paraesthesia—Etoposide—urinary bladder cancer	0.000351	0.000875	CcSEcCtD
Reboxetine—Weight decreased—Epirubicin—urinary bladder cancer	0.000348	0.000869	CcSEcCtD
Reboxetine—Dyspnoea—Etoposide—urinary bladder cancer	0.000348	0.000869	CcSEcCtD
Reboxetine—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000347	0.000867	CcSEcCtD
Reboxetine—Somnolence—Etoposide—urinary bladder cancer	0.000347	0.000867	CcSEcCtD
Reboxetine—Epistaxis—Methotrexate—urinary bladder cancer	0.000346	0.000864	CcSEcCtD
Reboxetine—Vomiting—Thiotepa—urinary bladder cancer	0.000346	0.000863	CcSEcCtD
Reboxetine—Infestation NOS—Epirubicin—urinary bladder cancer	0.000343	0.000857	CcSEcCtD
Reboxetine—Infestation—Epirubicin—urinary bladder cancer	0.000343	0.000857	CcSEcCtD
Reboxetine—Rash—Thiotepa—urinary bladder cancer	0.000343	0.000856	CcSEcCtD
Reboxetine—Bronchitis—Doxorubicin—urinary bladder cancer	0.000343	0.000855	CcSEcCtD
Reboxetine—Dermatitis—Thiotepa—urinary bladder cancer	0.000343	0.000855	CcSEcCtD
Reboxetine—Headache—Thiotepa—urinary bladder cancer	0.000341	0.00085	CcSEcCtD
Reboxetine—Decreased appetite—Etoposide—urinary bladder cancer	0.00034	0.000848	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000337	0.000842	CcSEcCtD
Reboxetine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000337	0.000841	CcSEcCtD
Reboxetine—Constipation—Etoposide—urinary bladder cancer	0.000334	0.000834	CcSEcCtD
Reboxetine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000334	0.000833	CcSEcCtD
Reboxetine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000334	0.000833	CcSEcCtD
Reboxetine—Dysuria—Doxorubicin—urinary bladder cancer	0.000333	0.000832	CcSEcCtD
Reboxetine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000331	0.000827	CcSEcCtD
Reboxetine—Sweating—Epirubicin—urinary bladder cancer	0.000329	0.000822	CcSEcCtD
Reboxetine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000329	0.000821	CcSEcCtD
Reboxetine—Asthenia—Gemcitabine—urinary bladder cancer	0.000328	0.000819	CcSEcCtD
Reboxetine—Pharyngitis—Methotrexate—urinary bladder cancer	0.000327	0.000816	CcSEcCtD
Reboxetine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000325	0.000812	CcSEcCtD
Reboxetine—Epistaxis—Epirubicin—urinary bladder cancer	0.000324	0.000808	CcSEcCtD
Reboxetine—Nausea—Thiotepa—urinary bladder cancer	0.000323	0.000806	CcSEcCtD
Reboxetine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000323	0.000806	CcSEcCtD
Reboxetine—Weight decreased—Doxorubicin—urinary bladder cancer	0.000322	0.000805	CcSEcCtD
Reboxetine—Sinusitis—Epirubicin—urinary bladder cancer	0.000322	0.000804	CcSEcCtD
Reboxetine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000322	0.000803	CcSEcCtD
Reboxetine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000321	0.000802	CcSEcCtD
Reboxetine—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.00032	0.00867	CbGpPWpGaD
Reboxetine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00032	0.000797	CcSEcCtD
Reboxetine—Infestation—Doxorubicin—urinary bladder cancer	0.000318	0.000793	CcSEcCtD
Reboxetine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000318	0.000793	CcSEcCtD
Reboxetine—Visual impairment—Methotrexate—urinary bladder cancer	0.000317	0.000792	CcSEcCtD
Reboxetine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000314	0.000784	CcSEcCtD
Reboxetine—Bradycardia—Epirubicin—urinary bladder cancer	0.000314	0.000783	CcSEcCtD
Reboxetine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000313	0.000781	CcSEcCtD
Reboxetine—Urticaria—Etoposide—urinary bladder cancer	0.00031	0.000775	CcSEcCtD
Reboxetine—Rhinitis—Epirubicin—urinary bladder cancer	0.000309	0.000771	CcSEcCtD
Reboxetine—Body temperature increased—Etoposide—urinary bladder cancer	0.000309	0.000771	CcSEcCtD
Reboxetine—Abdominal pain—Etoposide—urinary bladder cancer	0.000309	0.000771	CcSEcCtD
Reboxetine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000309	0.000771	CcSEcCtD
Reboxetine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000309	0.000771	CcSEcCtD
Reboxetine—Eye disorder—Methotrexate—urinary bladder cancer	0.000308	0.000768	CcSEcCtD
Reboxetine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000308	0.000768	CcSEcCtD
Reboxetine—Tinnitus—Methotrexate—urinary bladder cancer	0.000307	0.000766	CcSEcCtD
Reboxetine—Asthenia—Cisplatin—urinary bladder cancer	0.000306	0.000764	CcSEcCtD
Reboxetine—Pharyngitis—Epirubicin—urinary bladder cancer	0.000306	0.000763	CcSEcCtD
Reboxetine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000306	0.000763	CcSEcCtD
Reboxetine—Sweating—Doxorubicin—urinary bladder cancer	0.000305	0.00076	CcSEcCtD
Reboxetine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000304	0.00076	CcSEcCtD
Reboxetine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000303	0.000756	CcSEcCtD
Reboxetine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000302	0.000754	CcSEcCtD
Reboxetine—Epistaxis—Doxorubicin—urinary bladder cancer	0.0003	0.000748	CcSEcCtD
Reboxetine—Angiopathy—Methotrexate—urinary bladder cancer	0.000299	0.000746	CcSEcCtD
Reboxetine—Sinusitis—Doxorubicin—urinary bladder cancer	0.000298	0.000744	CcSEcCtD
Reboxetine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000298	0.000742	CcSEcCtD
Reboxetine—Dizziness—Fluorouracil—urinary bladder cancer	0.000298	0.000742	CcSEcCtD
Reboxetine—Visual impairment—Epirubicin—urinary bladder cancer	0.000297	0.000741	CcSEcCtD
Reboxetine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000297	0.000741	CcSEcCtD
Reboxetine—Chills—Methotrexate—urinary bladder cancer	0.000296	0.000738	CcSEcCtD
Reboxetine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000292	0.000728	CcSEcCtD
Reboxetine—Vomiting—Gemcitabine—urinary bladder cancer	0.000291	0.000726	CcSEcCtD
Reboxetine—Bradycardia—Doxorubicin—urinary bladder cancer	0.00029	0.000725	CcSEcCtD
Reboxetine—Mental disorder—Methotrexate—urinary bladder cancer	0.000289	0.00072	CcSEcCtD
Reboxetine—Rash—Gemcitabine—urinary bladder cancer	0.000289	0.00072	CcSEcCtD
Reboxetine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000288	0.000719	CcSEcCtD
Reboxetine—Eye disorder—Epirubicin—urinary bladder cancer	0.000288	0.000719	CcSEcCtD
Reboxetine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000288	0.000718	CcSEcCtD
Reboxetine—Tinnitus—Epirubicin—urinary bladder cancer	0.000287	0.000717	CcSEcCtD
Reboxetine—Malnutrition—Methotrexate—urinary bladder cancer	0.000287	0.000716	CcSEcCtD
Reboxetine—Headache—Gemcitabine—urinary bladder cancer	0.000287	0.000715	CcSEcCtD
Reboxetine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000286	0.000714	CcSEcCtD
Reboxetine—Vomiting—Fluorouracil—urinary bladder cancer	0.000286	0.000714	CcSEcCtD
Reboxetine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000286	0.000714	CcSEcCtD
Reboxetine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000285	0.00772	CbGpPWpGaD
Reboxetine—Rash—Fluorouracil—urinary bladder cancer	0.000284	0.000708	CcSEcCtD
Reboxetine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000283	0.000707	CcSEcCtD
Reboxetine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000283	0.000706	CcSEcCtD
Reboxetine—Headache—Fluorouracil—urinary bladder cancer	0.000282	0.000703	CcSEcCtD
Reboxetine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000282	0.000703	CcSEcCtD
Reboxetine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000281	0.000701	CcSEcCtD
Reboxetine—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000281	0.00762	CbGpPWpGaD
Reboxetine—Asthenia—Etoposide—urinary bladder cancer	0.00028	0.0007	CcSEcCtD
Reboxetine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00028	0.000699	CcSEcCtD
Reboxetine—Angiopathy—Epirubicin—urinary bladder cancer	0.00028	0.000698	CcSEcCtD
Reboxetine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00028	0.000698	CcSEcCtD
Reboxetine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000278	0.000695	CcSEcCtD
Reboxetine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000278	0.000693	CcSEcCtD
Reboxetine—Chills—Epirubicin—urinary bladder cancer	0.000277	0.00069	CcSEcCtD
Reboxetine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000275	0.000686	CcSEcCtD
Reboxetine—Nausea—Gemcitabine—urinary bladder cancer	0.000272	0.000678	CcSEcCtD
Reboxetine—Vomiting—Cisplatin—urinary bladder cancer	0.000271	0.000677	CcSEcCtD
Reboxetine—Mental disorder—Epirubicin—urinary bladder cancer	0.00027	0.000674	CcSEcCtD
Reboxetine—Rash—Cisplatin—urinary bladder cancer	0.000269	0.000671	CcSEcCtD
Reboxetine—Dermatitis—Cisplatin—urinary bladder cancer	0.000269	0.00067	CcSEcCtD
Reboxetine—Malnutrition—Epirubicin—urinary bladder cancer	0.000268	0.00067	CcSEcCtD
Reboxetine—Diarrhoea—Etoposide—urinary bladder cancer	0.000267	0.000667	CcSEcCtD
Reboxetine—Nausea—Fluorouracil—urinary bladder cancer	0.000267	0.000667	CcSEcCtD
Reboxetine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000267	0.000665	CcSEcCtD
Reboxetine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000266	0.000664	CcSEcCtD
Reboxetine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000266	0.000664	CcSEcCtD
Reboxetine—Anaemia—Methotrexate—urinary bladder cancer	0.000265	0.000661	CcSEcCtD
Reboxetine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000265	0.000661	CcSEcCtD
Reboxetine—Tension—Epirubicin—urinary bladder cancer	0.000263	0.000657	CcSEcCtD
Reboxetine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000263	0.000656	CcSEcCtD
Reboxetine—Nervousness—Epirubicin—urinary bladder cancer	0.000261	0.00065	CcSEcCtD
Reboxetine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000259	0.000646	CcSEcCtD
Reboxetine—Malaise—Methotrexate—urinary bladder cancer	0.000259	0.000645	CcSEcCtD
Reboxetine—Dizziness—Etoposide—urinary bladder cancer	0.000258	0.000645	CcSEcCtD
Reboxetine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000258	0.000643	CcSEcCtD
Reboxetine—Vertigo—Methotrexate—urinary bladder cancer	0.000258	0.000643	CcSEcCtD
Reboxetine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000257	0.000641	CcSEcCtD
Reboxetine—SLC6A4—NRF2 pathway—NQO1—urinary bladder cancer	0.000257	0.00696	CbGpPWpGaD
Reboxetine—Leukopenia—Methotrexate—urinary bladder cancer	0.000257	0.000641	CcSEcCtD
Reboxetine—Chills—Doxorubicin—urinary bladder cancer	0.000256	0.000639	CcSEcCtD
Reboxetine—Nausea—Cisplatin—urinary bladder cancer	0.000253	0.000632	CcSEcCtD
Reboxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—KRAS—urinary bladder cancer	0.000253	0.00685	CbGpPWpGaD
Reboxetine—SLC6A4—Monoamine Transport—TNF—urinary bladder cancer	0.000252	0.00684	CbGpPWpGaD
Reboxetine—Mental disorder—Doxorubicin—urinary bladder cancer	0.00025	0.000624	CcSEcCtD
Reboxetine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000249	0.000621	CcSEcCtD
Reboxetine—Vomiting—Etoposide—urinary bladder cancer	0.000248	0.00062	CcSEcCtD
Reboxetine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000248	0.00062	CcSEcCtD
Reboxetine—Anaemia—Epirubicin—urinary bladder cancer	0.000248	0.000619	CcSEcCtD
Reboxetine—Agitation—Epirubicin—urinary bladder cancer	0.000247	0.000615	CcSEcCtD
Reboxetine—Rash—Etoposide—urinary bladder cancer	0.000246	0.000615	CcSEcCtD
Reboxetine—Dermatitis—Etoposide—urinary bladder cancer	0.000246	0.000614	CcSEcCtD
Reboxetine—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000245	0.00665	CbGpPWpGaD
Reboxetine—Headache—Etoposide—urinary bladder cancer	0.000245	0.000611	CcSEcCtD
Reboxetine—Chest pain—Methotrexate—urinary bladder cancer	0.000244	0.000609	CcSEcCtD
Reboxetine—Tension—Doxorubicin—urinary bladder cancer	0.000244	0.000608	CcSEcCtD
Reboxetine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000243	0.000607	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000242	0.000605	CcSEcCtD
Reboxetine—Malaise—Epirubicin—urinary bladder cancer	0.000242	0.000604	CcSEcCtD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000242	0.00656	CbGpPWpGaD
Reboxetine—Discomfort—Methotrexate—urinary bladder cancer	0.000241	0.000602	CcSEcCtD
Reboxetine—Nervousness—Doxorubicin—urinary bladder cancer	0.000241	0.000602	CcSEcCtD
Reboxetine—Vertigo—Epirubicin—urinary bladder cancer	0.000241	0.000602	CcSEcCtD
Reboxetine—Syncope—Epirubicin—urinary bladder cancer	0.000241	0.000601	CcSEcCtD
Reboxetine—Leukopenia—Epirubicin—urinary bladder cancer	0.00024	0.000599	CcSEcCtD
Reboxetine—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.00024	0.00651	CbGpPWpGaD
Reboxetine—Palpitations—Epirubicin—urinary bladder cancer	0.000237	0.000592	CcSEcCtD
Reboxetine—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000237	0.00642	CbGpPWpGaD
Reboxetine—Confusional state—Methotrexate—urinary bladder cancer	0.000236	0.000589	CcSEcCtD
Reboxetine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000236	0.000589	CcSEcCtD
Reboxetine—Infection—Methotrexate—urinary bladder cancer	0.000233	0.00058	CcSEcCtD
Reboxetine—Nausea—Etoposide—urinary bladder cancer	0.000232	0.000579	CcSEcCtD
Reboxetine—Hypertension—Epirubicin—urinary bladder cancer	0.000232	0.000578	CcSEcCtD
Reboxetine—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000231	0.00626	CbGpPWpGaD
Reboxetine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00023	0.000575	CcSEcCtD
Reboxetine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00023	0.00623	CbGpPWpGaD
Reboxetine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00023	0.000573	CcSEcCtD
Reboxetine—Anaemia—Doxorubicin—urinary bladder cancer	0.00023	0.000573	CcSEcCtD
Reboxetine—Chest pain—Epirubicin—urinary bladder cancer	0.000228	0.00057	CcSEcCtD
Reboxetine—Agitation—Doxorubicin—urinary bladder cancer	0.000228	0.000569	CcSEcCtD
Reboxetine—Anxiety—Epirubicin—urinary bladder cancer	0.000228	0.000568	CcSEcCtD
Reboxetine—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000228	0.00617	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000228	0.00617	CbGpPWpGaD
Reboxetine—Skin disorder—Methotrexate—urinary bladder cancer	0.000227	0.000567	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000227	0.000566	CcSEcCtD
Reboxetine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000226	0.000565	CcSEcCtD
Reboxetine—Discomfort—Epirubicin—urinary bladder cancer	0.000226	0.000563	CcSEcCtD
Reboxetine—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000224	0.00609	CbGpPWpGaD
Reboxetine—Malaise—Doxorubicin—urinary bladder cancer	0.000224	0.000559	CcSEcCtD
Reboxetine—Dry mouth—Epirubicin—urinary bladder cancer	0.000223	0.000558	CcSEcCtD
Reboxetine—Vertigo—Doxorubicin—urinary bladder cancer	0.000223	0.000557	CcSEcCtD
Reboxetine—Anorexia—Methotrexate—urinary bladder cancer	0.000223	0.000557	CcSEcCtD
Reboxetine—Syncope—Doxorubicin—urinary bladder cancer	0.000223	0.000556	CcSEcCtD
Reboxetine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000222	0.000555	CcSEcCtD
Reboxetine—Confusional state—Epirubicin—urinary bladder cancer	0.000221	0.000551	CcSEcCtD
Reboxetine—SLC6A2—NRF2 pathway—NQO1—urinary bladder cancer	0.000221	0.00599	CbGpPWpGaD
Reboxetine—Palpitations—Doxorubicin—urinary bladder cancer	0.000219	0.000548	CcSEcCtD
Reboxetine—Hypotension—Methotrexate—urinary bladder cancer	0.000219	0.000546	CcSEcCtD
Reboxetine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000218	0.000545	CcSEcCtD
Reboxetine—Infection—Epirubicin—urinary bladder cancer	0.000218	0.000543	CcSEcCtD
Reboxetine—SLC6A2—Monoamine Transport—TNF—urinary bladder cancer	0.000217	0.00588	CbGpPWpGaD
Reboxetine—Shock—Epirubicin—urinary bladder cancer	0.000215	0.000538	CcSEcCtD
Reboxetine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000215	0.000536	CcSEcCtD
Reboxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—urinary bladder cancer	0.000215	0.00582	CbGpPWpGaD
Reboxetine—Hypertension—Doxorubicin—urinary bladder cancer	0.000214	0.000535	CcSEcCtD
Reboxetine—SLC6A4—NRF2 pathway—GSTP1—urinary bladder cancer	0.000214	0.00581	CbGpPWpGaD
Reboxetine—Tachycardia—Epirubicin—urinary bladder cancer	0.000214	0.000533	CcSEcCtD
Reboxetine—Skin disorder—Epirubicin—urinary bladder cancer	0.000213	0.000531	CcSEcCtD
Reboxetine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000212	0.000528	CcSEcCtD
Reboxetine—Insomnia—Methotrexate—urinary bladder cancer	0.000212	0.000528	CcSEcCtD
Reboxetine—Chest pain—Doxorubicin—urinary bladder cancer	0.000211	0.000528	CcSEcCtD
Reboxetine—Anxiety—Doxorubicin—urinary bladder cancer	0.000211	0.000526	CcSEcCtD
Reboxetine—Paraesthesia—Methotrexate—urinary bladder cancer	0.00021	0.000524	CcSEcCtD
Reboxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00021	0.000524	CcSEcCtD
Reboxetine—Discomfort—Doxorubicin—urinary bladder cancer	0.000209	0.000521	CcSEcCtD
Reboxetine—Anorexia—Epirubicin—urinary bladder cancer	0.000209	0.000521	CcSEcCtD
Reboxetine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000209	0.000521	CcSEcCtD
Reboxetine—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000208	0.00565	CbGpPWpGaD
Reboxetine—Somnolence—Methotrexate—urinary bladder cancer	0.000208	0.000519	CcSEcCtD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000207	0.00561	CbGpPWpGaD
Reboxetine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000207	0.000516	CcSEcCtD
Reboxetine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000206	0.000514	CcSEcCtD
Reboxetine—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000205	0.00557	CbGpPWpGaD
Reboxetine—Hypotension—Epirubicin—urinary bladder cancer	0.000205	0.000511	CcSEcCtD
Reboxetine—Confusional state—Doxorubicin—urinary bladder cancer	0.000204	0.00051	CcSEcCtD
Reboxetine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000203	0.000508	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000202	0.000504	CcSEcCtD
Reboxetine—Infection—Doxorubicin—urinary bladder cancer	0.000201	0.000502	CcSEcCtD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.0002	0.00543	CbGpPWpGaD
Reboxetine—Shock—Doxorubicin—urinary bladder cancer	0.000199	0.000498	CcSEcCtD
Reboxetine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000199	0.000496	CcSEcCtD
Reboxetine—Insomnia—Epirubicin—urinary bladder cancer	0.000198	0.000494	CcSEcCtD
Reboxetine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000198	0.000494	CcSEcCtD
Reboxetine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000197	0.000491	CcSEcCtD
Reboxetine—SLC6A4—NRF2 pathway—GSTM1—urinary bladder cancer	0.000197	0.00534	CbGpPWpGaD
Reboxetine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000197	0.000491	CcSEcCtD
Reboxetine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000196	0.000489	CcSEcCtD
Reboxetine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000195	0.000487	CcSEcCtD
Reboxetine—Somnolence—Epirubicin—urinary bladder cancer	0.000195	0.000486	CcSEcCtD
Reboxetine—Anorexia—Doxorubicin—urinary bladder cancer	0.000193	0.000482	CcSEcCtD
Reboxetine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000193	0.000481	CcSEcCtD
Reboxetine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000193	0.000481	CcSEcCtD
Reboxetine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000191	0.000478	CcSEcCtD
Reboxetine—Decreased appetite—Epirubicin—urinary bladder cancer	0.00019	0.000475	CcSEcCtD
Reboxetine—Hypotension—Doxorubicin—urinary bladder cancer	0.000189	0.000473	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000189	0.000472	CcSEcCtD
Reboxetine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000187	0.00508	CbGpPWpGaD
Reboxetine—Constipation—Epirubicin—urinary bladder cancer	0.000187	0.000467	CcSEcCtD
Reboxetine—Urticaria—Methotrexate—urinary bladder cancer	0.000186	0.000464	CcSEcCtD
Reboxetine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000185	0.000462	CcSEcCtD
Reboxetine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000185	0.000462	CcSEcCtD
Reboxetine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000185	0.00501	CbGpPWpGaD
Reboxetine—SLC6A2—NRF2 pathway—GSTP1—urinary bladder cancer	0.000184	0.00499	CbGpPWpGaD
Reboxetine—Insomnia—Doxorubicin—urinary bladder cancer	0.000183	0.000457	CcSEcCtD
Reboxetine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000182	0.000454	CcSEcCtD
Reboxetine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000181	0.000451	CcSEcCtD
Reboxetine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00018	0.00045	CcSEcCtD
Reboxetine—Somnolence—Doxorubicin—urinary bladder cancer	0.00018	0.00045	CcSEcCtD
Reboxetine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000179	0.000447	CcSEcCtD
Reboxetine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000178	0.000445	CcSEcCtD
Reboxetine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000176	0.00044	CcSEcCtD
Reboxetine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000175	0.000437	CcSEcCtD
Reboxetine—Urticaria—Epirubicin—urinary bladder cancer	0.000174	0.000434	CcSEcCtD
Reboxetine—Constipation—Doxorubicin—urinary bladder cancer	0.000173	0.000432	CcSEcCtD
Reboxetine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000173	0.000432	CcSEcCtD
Reboxetine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000173	0.000432	CcSEcCtD
Reboxetine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000172	0.00043	CcSEcCtD
Reboxetine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000171	0.00465	CbGpPWpGaD
Reboxetine—SLC6A2—NRF2 pathway—GSTM1—urinary bladder cancer	0.000169	0.00459	CbGpPWpGaD
Reboxetine—Asthenia—Methotrexate—urinary bladder cancer	0.000168	0.000419	CcSEcCtD
Reboxetine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000167	0.000417	CcSEcCtD
Reboxetine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000166	0.000414	CcSEcCtD
Reboxetine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000161	0.000403	CcSEcCtD
Reboxetine—Urticaria—Doxorubicin—urinary bladder cancer	0.000161	0.000402	CcSEcCtD
Reboxetine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00016	0.0004	CcSEcCtD
Reboxetine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.00016	0.0004	CcSEcCtD
Reboxetine—Diarrhoea—Methotrexate—urinary bladder cancer	0.00016	0.0004	CcSEcCtD
Reboxetine—Asthenia—Epirubicin—urinary bladder cancer	0.000157	0.000392	CcSEcCtD
Reboxetine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000157	0.00426	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000155	0.0042	CbGpPWpGaD
Reboxetine—Dizziness—Methotrexate—urinary bladder cancer	0.000155	0.000386	CcSEcCtD
Reboxetine—SLC6A4—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000154	0.00418	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000152	0.00413	CbGpPWpGaD
Reboxetine—Diarrhoea—Epirubicin—urinary bladder cancer	0.00015	0.000374	CcSEcCtD
Reboxetine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000149	0.000373	CcSEcCtD
Reboxetine—Vomiting—Methotrexate—urinary bladder cancer	0.000149	0.000371	CcSEcCtD
Reboxetine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000149	0.00404	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000149	0.00404	CbGpPWpGaD
Reboxetine—Rash—Methotrexate—urinary bladder cancer	0.000148	0.000368	CcSEcCtD
Reboxetine—Dermatitis—Methotrexate—urinary bladder cancer	0.000147	0.000368	CcSEcCtD
Reboxetine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000147	0.00398	CbGpPWpGaD
Reboxetine—Headache—Methotrexate—urinary bladder cancer	0.000147	0.000366	CcSEcCtD
Reboxetine—Asthenia—Doxorubicin—urinary bladder cancer	0.000145	0.000363	CcSEcCtD
Reboxetine—Dizziness—Epirubicin—urinary bladder cancer	0.000145	0.000361	CcSEcCtD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000145	0.00393	CbGpPWpGaD
Reboxetine—Vomiting—Epirubicin—urinary bladder cancer	0.000139	0.000347	CcSEcCtD
Reboxetine—Nausea—Methotrexate—urinary bladder cancer	0.000139	0.000347	CcSEcCtD
Reboxetine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000139	0.000346	CcSEcCtD
Reboxetine—Rash—Epirubicin—urinary bladder cancer	0.000138	0.000345	CcSEcCtD
Reboxetine—Dermatitis—Epirubicin—urinary bladder cancer	0.000138	0.000344	CcSEcCtD
Reboxetine—Headache—Epirubicin—urinary bladder cancer	0.000137	0.000342	CcSEcCtD
Reboxetine—SLC6A4—Circadian rythm related genes—FAS—urinary bladder cancer	0.000137	0.0037	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000136	0.00369	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000134	0.00364	CbGpPWpGaD
Reboxetine—Dizziness—Doxorubicin—urinary bladder cancer	0.000134	0.000334	CcSEcCtD
Reboxetine—Nausea—Epirubicin—urinary bladder cancer	0.00013	0.000325	CcSEcCtD
Reboxetine—Vomiting—Doxorubicin—urinary bladder cancer	0.000129	0.000322	CcSEcCtD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000128	0.00348	CbGpPWpGaD
Reboxetine—Rash—Doxorubicin—urinary bladder cancer	0.000128	0.000319	CcSEcCtD
Reboxetine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000128	0.000319	CcSEcCtD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000128	0.00346	CbGpPWpGaD
Reboxetine—Headache—Doxorubicin—urinary bladder cancer	0.000127	0.000317	CcSEcCtD
Reboxetine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000125	0.00338	CbGpPWpGaD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.000124	0.00336	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000123	0.00334	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000123	0.00332	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000121	0.00328	CbGpPWpGaD
Reboxetine—Nausea—Doxorubicin—urinary bladder cancer	0.00012	0.0003	CcSEcCtD
Reboxetine—SLC6A4—Circadian rythm related genes—CDK4—urinary bladder cancer	0.00012	0.00326	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000118	0.0032	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000109	0.00296	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	0.000109	0.00296	CbGpPWpGaD
Reboxetine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000106	0.00286	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000102	0.00277	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	9.97e-05	0.0027	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	9.73e-05	0.00264	CbGpPWpGaD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	9.68e-05	0.00263	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	9.67e-05	0.00262	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	9.67e-05	0.00262	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	8.82e-05	0.00239	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	8.75e-05	0.00237	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	8.15e-05	0.00221	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	8.04e-05	0.00218	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.97e-05	0.00216	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	7.78e-05	0.00211	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—PTEN—urinary bladder cancer	7.49e-05	0.00203	CbGpPWpGaD
Reboxetine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	7.29e-05	0.00198	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—EP300—urinary bladder cancer	7.14e-05	0.00194	CbGpPWpGaD
Reboxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	7.1e-05	0.00193	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	6.7e-05	0.00182	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	6.66e-05	0.00181	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.61e-05	0.00179	CbGpPWpGaD
Reboxetine—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	6.59e-05	0.00179	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	6.52e-05	0.00177	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	6.37e-05	0.00173	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	6.36e-05	0.00173	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	6.32e-05	0.00171	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	6.19e-05	0.00168	CbGpPWpGaD
Reboxetine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	6.16e-05	0.00167	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	6.08e-05	0.00165	CbGpPWpGaD
Reboxetine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.07e-05	0.00165	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	5.39e-05	0.00146	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	5.2e-05	0.00141	CbGpPWpGaD
Reboxetine—SLC6A4—Circadian rythm related genes—TP53—urinary bladder cancer	5.11e-05	0.00139	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.76e-05	0.00129	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.74e-05	0.00129	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.72e-05	0.00128	CbGpPWpGaD
Reboxetine—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	4.63e-05	0.00126	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—HDAC4—urinary bladder cancer	4.57e-05	0.00124	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	4.38e-05	0.00119	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	4.36e-05	0.00118	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.32e-05	0.00117	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	4.14e-05	0.00112	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTO2—urinary bladder cancer	4.13e-05	0.00112	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NAT1—urinary bladder cancer	4.13e-05	0.00112	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	4.1e-05	0.00111	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	4.09e-05	0.00111	CbGpPWpGaD
Reboxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	4.05e-05	0.0011	CbGpPWpGaD
Reboxetine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	4.03e-05	0.00109	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	4e-05	0.00108	CbGpPWpGaD
Reboxetine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.97e-05	0.00108	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	3.89e-05	0.00106	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	3.89e-05	0.00106	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—GLI1—urinary bladder cancer	3.83e-05	0.00104	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	3.78e-05	0.00102	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	3.78e-05	0.00102	CbGpPWpGaD
Reboxetine—SLC6A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.73e-05	0.00101	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	3.56e-05	0.000966	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.51e-05	0.000952	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.46e-05	0.00094	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	3.4e-05	0.000923	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.39e-05	0.000919	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	3.21e-05	0.000871	CbGpPWpGaD
Reboxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	3.21e-05	0.000871	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	3.2e-05	0.000869	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PRSS3—urinary bladder cancer	3.13e-05	0.000849	CbGpPWpGaD
Reboxetine—HTR2C—GPCR ligand binding—CXCL8—urinary bladder cancer	3.08e-05	0.000837	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.06e-05	0.00083	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	3.03e-05	0.000821	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.96e-05	0.000803	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.95e-05	0.000801	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	2.95e-05	0.0008	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.82e-05	0.000764	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.74e-05	0.000743	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.68e-05	0.000728	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—RBX1—urinary bladder cancer	2.62e-05	0.000712	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.54e-05	0.00069	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.54e-05	0.00069	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.5e-05	0.000679	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TSC1—urinary bladder cancer	2.47e-05	0.000669	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.46e-05	0.000666	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.4e-05	0.000651	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	2.36e-05	0.00064	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—JAG1—urinary bladder cancer	2.35e-05	0.000637	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.33e-05	0.000631	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.29e-05	0.00062	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.27e-05	0.000615	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.26e-05	0.000614	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	2.13e-05	0.000578	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.1e-05	0.000568	CbGpPWpGaD
Reboxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.02e-05	0.000547	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—RHOA—urinary bladder cancer	1.99e-05	0.000539	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.98e-05	0.000537	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.95e-05	0.00053	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.93e-05	0.000523	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—S100B—urinary bladder cancer	1.9e-05	0.000516	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.84e-05	0.000499	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.81e-05	0.000491	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.81e-05	0.000491	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—RHOA—urinary bladder cancer	1.8e-05	0.000489	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.75e-05	0.000476	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.74e-05	0.000473	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—NCOR1—urinary bladder cancer	1.71e-05	0.000464	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.7e-05	0.000462	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.7e-05	0.000462	CbGpPWpGaD
Reboxetine—HTR2C—GPCR downstream signaling—IL2—urinary bladder cancer	1.67e-05	0.000452	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.65e-05	0.000449	CbGpPWpGaD
Reboxetine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.64e-05	0.000446	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—CXCL8—urinary bladder cancer	1.58e-05	0.000429	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.54e-05	0.000418	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—IL2—urinary bladder cancer	1.51e-05	0.00041	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TERT—urinary bladder cancer	1.51e-05	0.000409	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.46e-05	0.000396	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.39e-05	0.000378	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—FGFR3—urinary bladder cancer	1.38e-05	0.000375	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.37e-05	0.000373	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ESR1—urinary bladder cancer	1.34e-05	0.000364	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.22e-05	0.00033	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.2e-05	0.000326	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	1.18e-05	0.000319	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	1.16e-05	0.000315	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	1.16e-05	0.000314	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.15e-05	0.000311	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.13e-05	0.000307	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.12e-05	0.000303	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.12e-05	0.000303	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.11e-05	0.000302	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.11e-05	0.000302	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.09e-05	0.000297	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.08e-05	0.000293	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.07e-05	0.00029	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.07e-05	0.000289	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	1.07e-05	0.000289	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.05e-05	0.000286	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.05e-05	0.000286	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.05e-05	0.000285	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.01e-05	0.000274	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	9.9e-06	0.000269	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	9.88e-06	0.000268	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	9.86e-06	0.000268	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	9.35e-06	0.000254	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	9.31e-06	0.000252	CbGpPWpGaD
Reboxetine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	9.29e-06	0.000252	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.98e-06	0.000244	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	8.94e-06	0.000242	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	8.71e-06	0.000236	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	8.46e-06	0.000229	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	8.43e-06	0.000229	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	8.41e-06	0.000228	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	8.02e-06	0.000218	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.01e-06	0.000217	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	7.8e-06	0.000212	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.69e-06	0.000209	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	7.55e-06	0.000205	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.49e-06	0.000203	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	7.25e-06	0.000197	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	6.99e-06	0.00019	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.97e-06	0.000189	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.89e-06	0.000187	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.89e-06	0.000187	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	6.84e-06	0.000185	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.59e-06	0.000179	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.47e-06	0.000176	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	6.46e-06	0.000175	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.3e-06	0.000171	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.08e-06	0.000165	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.94e-06	0.000161	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	5.74e-06	0.000156	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.49e-06	0.000149	CbGpPWpGaD
Reboxetine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	5.49e-06	0.000149	CbGpPWpGaD
Reboxetine—ABCB1—Metabolism—EP300—urinary bladder cancer	5.24e-06	0.000142	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	5.18e-06	0.00014	CbGpPWpGaD
Reboxetine—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.94e-06	0.000134	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.93e-06	0.000134	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.74e-06	0.000129	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.88e-06	0.000105	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.39e-06	9.18e-05	CbGpPWpGaD
Reboxetine—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.23e-06	8.76e-05	CbGpPWpGaD
